This article contains findings obtained from research on animals:
- The results from animal research studies should not be directly applied to humans and the results may not generalise to the human population.
- There may be significant differences between species in terms of physiology, physiology, and pharmacology, as well as differences in the way diseases and treatments are modelled in animals.
- Any conclusions drawn from animal research should be considered with caution and in the context of other types of research studies such as observational studies, clinical trials, and reviews of the literature.
Insights & Discussion
Discover Related Insights
Kiwifruit polysaccharides may alleviate the toxic effects of acrylamide by improving gut health and enhancing bile acid metabolism.
2023 Frontiers in Nutrition Effects of kiwi fruit (Actinidia chinensis) polysaccharides on metabolites and gut microbiota of acrylamide-induced mice Chen M, Chen X, Wang K, Cai L, Liu N, Zhou D, et al.
Animal Study Bile Acid Gut Microbiota Kiwifruit
In this study, the team explored the potential protective effects of kiwifruit polysaccharides on disorders induced by acrylamide (a toxic ingredient found in high-temperature, carbohydrate-rich food) on gut microbiota and systemic metabolism. They measured changes in gut microbiota and serum metabolites in mice subjected to acrylamide-induced toxicity, focusing primarily on the effects on mice's bodily features, liver health, and liver enzyme activity.
The results revealed that treatment with kiwifruit polysaccharides not only improved the mice's overall health and liver function but also restored the balance in their gut microbiota by increasing microbial diversity and the abundance of beneficial bacteria. Furthermore, it was found that the polysaccharides had a significant impact on amino and bile acid-related metabolic pathways, proving their potential in protecting against toxicity. A strong correlation was also found between certain bacteria and the critical metabolites of bile acid metabolism, providing a deeper understanding of the protective mechanisms of kiwifruit polysaccharides.
Consuming two SunGold kiwifruits daily over 12 weeks improved vitamin C status, reduced blood pressure, waist measurements and altered faecal microbiota composition in prediabetic individuals.
2018 Nutrients SunGold Kiwifruit Supplementation of Individuals with Prediabetes Alters Gut Microbiota and Improves Vitamin C Status, Anthropometric and Clinical Markers Wilson R, Willis J, Gearry R, Hughes A, Lawley B, Skidmore P, et al.
Randomised Controlled Trial Gut Microbiota High Blood Pressure Kiwifruit
Over a 12 week pilot intervention trial, people with prediabetes were observed after consuming two SunGold kiwifruits per day. Participants filled out a physical activity questionnaire and a three-day estimated food diary at both the commencement and end of the trial. Venous blood samples were collected at the start, in between (at 6 weeks) and at the end of the trial, to observe glycaemic indices, plasma vitamin C concentrations, hormones, lipid profiles and high-sensitivity C-reactive protein levels. Additionally, participants provided faecal samples at each visit for DNA extraction and subsequent amplification and sequencing of a region of the 16S ribosomal RNA gene to determine faecal microbiota composition.
The differences were then compared between week 12 and their baseline measurements revealing a significant increase in plasma vitamin C concentration. Further changes including significant reductions in both diastolic and systolic blood pressure as well as waist circumference and waist-to-hip ratio were recorded. Despite recording a slight drop in HbA1c levels and a minor increase in fasting glucose, the changes were small and not clinically significant. Moreover, the composition analysis of the faecal microbiota indicated an increase in the relative abundance of hitherto uncultivated, hence uncharacterised members of a particular bacterial family. These findings suggest that these unknown bacterial members could potentially have a functional relationship with the polysaccharides and polyphenols in kiwifruits.
Kiwifruits can relieve constipation and irritable bowel syndrome, potentially through protease-activated signaling, modulation of microflora, changes in colonic methane, bile flux, or mediation of inflammatory processes.
2017 Critical Reviews in Food Science and Nutrition Putative mechanisms of kiwifruit on maintenance of normal gastrointestinal function Bayer SB, Gearry RB, Drummond LN
Review Article Digestive Health Gut Microbiota Irritable Bowel Syndrome
The review outlines the physiological processes underlying constipation and irritable bowel syndrome, and discusses the nutritional composition of kiwifruits. It delves into recent advances made in the study of kiwifruits and their impact on abdominal comfort, with the focus being given to the effect of kiwifruit fibers on gastrointestinal health. The study also identified and examined certain gaps in the existing research, using indications from studies on other foods known to affect the gastrointestinal tract to derive possible mechanisms of kiwifruits' beneficial actions.
In discussing the results, the review observed that while the effect of kiwifruit fibers on gastrointestinal health is well established, the supposed increase in gastrointestinal motility caused by kiwifruits is yet to be fully characterized. Numerous potential mechanisms were invoked that could be contributing to the physiological effects observed - these included the induction of motility through protease-activated signaling, the modulation of microflora in the gut, alterations in colonic methane status or bile flux, and the mediation of inflammation within the gut.
Gold kiwifruit supplementation increases the abundance of the beneficial gut bacterium Faecalibacterium, which could potentially enhance gut microbiota composition and reduce inflammation.
2017 Journal of Nutritional Science Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: a randomised controlled human trial Blatchford P, Stoklosinski H, Eady S, Wallace A, Butts C, Gearry R, et al.
Randomised Controlled Trial Constipation Gut Microbiota Kiwifruit
This research was conducted on two groups of participants: one healthy and the other suffering from Functional Constipation (FC). The groups, one containing 20 individuals (one of whom did not complete the study) and the other 9, were given ACTAZIN™ green (in doses of 2400mg and 600mg) and Livaux™ (2400 mg) gold kiwifruit supplements, as well as a placebo in the form of isomalt. The study design was a randomized cross-over structure carried out over 4 weeks, with 2 weeks washout periods between each stage. Changes in faecal microbiota composition and metabolism were assessed using 16S RNA gene sequencing and Gas Chromatography (GC), and colonic pH was measured via SmartPill wireless motility capsules.
The baseline measurements showed that the composition of the faecal microbiota differed significantly between the two groups, with certain bacterial taxa such as Bacteroidales markedly more abundant in the healthy group, while others, including Ruminococcaceae, were more prevalent in the FC group. The clearest change affected by the nutrient supplementation was an increase in Faecalibacterium abundance in the FC group following Livaux™ supplementation, a result observed in nearly all participants in this group. As lower proportions of Faecalibacterium are often linked with gastrointestinal disorders, this increase suggests that the supplements could offer a strategy for ameliorating these conditions.